Hologic Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Hologic wird ein jährliches Gewinn- und Umsatzwachstum von 14.6% bzw. 5.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 16% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.1% betragen.

Wichtige Informationen

14.6%

Wachstumsrate der Gewinne

16.0%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	5.3%
Zukünftige Eigenkapitalrendite	18.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	30 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

Feb 06

Recent updates

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Sep 28

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Aug 29

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Jul 31

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Jul 18

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Jun 21

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

May 22

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Apr 25

What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?

Apr 10

Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher

Mar 13

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Feb 14

Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly

Jan 18

Is Now The Time To Look At Buying Hologic, Inc. (NASDAQ:HOLX)?

Jan 03

Shareholders Would Enjoy A Repeat Of Hologic's (NASDAQ:HOLX) Recent Growth In Returns

Dec 02

Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly

Oct 12

Is Hologic, Inc. (NASDAQ:HOLX) Potentially Undervalued?

Sep 27

Hologic announces $1B share buyback program

Sep 26

We Like Hologic's (NASDAQ:HOLX) Returns And Here's How They're Trending

Aug 27

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:HOLX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2026	4,510	930	1,137	1,222	11
9/30/2025	4,249	850	1,054	1,113	16
9/30/2024	4,033	784	924	925	16
3/30/2024	3,961	467	949	1,104	N/A
12/30/2023	3,969	515	859	1,018	N/A
9/30/2023	4,030	456	901	1,051	N/A
7/1/2023	4,038	484	832	961	N/A
4/1/2023	4,057	753	841	959	N/A
12/31/2022	4,466	990	1,696	1,815	N/A
9/24/2022	4,863	1,302	1,999	2,126	N/A
6/25/2022	5,226	1,512	2,283	2,423	N/A
3/26/2022	5,392	1,552	2,598	2,755	N/A
12/25/2021	5,494	1,716	2,068	2,245	N/A
9/25/2021	5,632	1,872	2,146	2,330	N/A
6/26/2021	5,663	2,038	2,108	2,307	N/A
3/27/2021	5,317	1,907	1,677	1,867	N/A
12/26/2020	4,536	1,384	1,263	1,433	N/A
9/26/2020	3,776	1,115	740	897	N/A
6/27/2020	3,295	497	573	702	N/A
3/28/2020	3,325	453	518	643	N/A
12/28/2019	3,387	84	536	659	N/A
9/28/2019	3,367	-204	536	650	N/A
6/29/2019	3,315	-30	520	634	N/A
3/30/2019	3,287	-11	596	705	N/A
12/29/2018	3,258	-419	562	668	N/A
9/29/2018	3,218	-111	627	733	N/A
6/30/2018	3,207	-79	560	667	N/A
3/31/2018	3,189	-132	-85	21	N/A
12/30/2017	3,116	1,076	N/A	8	N/A
9/30/2017	3,059	756	N/A	8	N/A
7/1/2017	2,983	765	N/A	70	N/A
4/1/2017	2,894	790	N/A	729	N/A
12/31/2016	2,872	332	N/A	796	N/A
9/24/2016	2,833	331	N/A	798	N/A
6/25/2016	2,809	264	N/A	802	N/A
3/26/2016	2,785	208	N/A	797	N/A
12/26/2015	2,747	187	N/A	804	N/A
9/26/2015	2,705	132	N/A	797	N/A
6/27/2015	2,641	135	N/A	685	N/A
3/28/2015	2,580	116	N/A	601	N/A
12/27/2014	2,549	52	N/A	513	N/A
9/27/2014	2,531	17	N/A	508	N/A
6/28/2014	2,477	-1,125	N/A	455	N/A
3/29/2014	2,470	-1,147	N/A	543	N/A
12/28/2013	2,458	-1,181	N/A	488	N/A
9/28/2013	2,492	-1,173	N/A	494	N/A
6/29/2013	2,459	-137	N/A	501	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HOLXDas prognostizierte Gewinnwachstum (14.6% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: HOLXDie Erträge des Unternehmens (14.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: HOLXDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: HOLXDie Einnahmen des Unternehmens (5.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: HOLXDie Einnahmen des Unternehmens (5.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: HOLXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.1%).

Hologic Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Consensus EPS estimates fall by 22%

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Recent updates

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

Hologic: Women's Health Play Looks Healthier Itself

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024

Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Now 20% undervalued

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Independent Director notifies of intention to sell stock

Now 20% undervalued

Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test

Now 20% undervalued

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic: Prospects For Growth As Headwinds Disappear

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)

Now 21% undervalued

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Now 21% undervalued

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Independent Director notifies of intention to sell stock

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Are Investors Undervaluing Hologic, Inc. (NASDAQ:HOLX) By 25%?

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Chairman exercised options and sold US$2.1m worth of stock

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Full year 2023 earnings: EPS misses analyst expectations

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares.

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Should You Think About Buying Hologic, Inc. (NASDAQ:HOLX) Now?

Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Consensus EPS estimates fall by 22%

Hologic, Inc. Reports Impairment Charges for the Third Quarter Ended July 1, 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic, Inc. to Report Q3, 2023 Results on Jul 31, 2023

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay

Insider recently sold US$200k worth of stock

Insider notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?

Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher

Hologic, Inc. Announces Approval of NovaSure V5 Global Endometrial Ablation Device in Canada and Europe

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Hologic, Inc. Provides Earnings Guidance for the Second Quarter of 2023

Hologic, Inc., Annual General Meeting, Mar 09, 2023

Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly

Hologic, Inc. Revises Revenue Results for the First Quarter of Fiscal 2023

Hologic, Inc. to Report Q1, 2023 Results on Feb 01, 2023